Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation

Detalhes bibliográficos
Autor(a) principal: Diaz, Ana Claudia Marques Barbosa
Data de Publicação: 2024
Outros Autores: Witkin, Steven Sol, Almeida Neto, Cesar de, Rocha, Vanderson, Costa, Silvia Figueiredo, Ramos, Jessica Fernandes, Mendes-Correa, Maria Cassia
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista do Instituto de Medicina Tropical de São Paulo
Texto Completo: https://www.revistas.usp.br/rimtsp/article/view/221851
Resumo: Hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation.
id IMT-1_57a05539ddbf7107026f335c1a60ebb8
oai_identifier_str oai:revistas.usp.br:article/221851
network_acronym_str IMT-1
network_name_str Revista do Instituto de Medicina Tropical de São Paulo
repository_id_str
spelling Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantationHepatitis CHematopoietic stem cell transplantationPrevalenceClinical outcomeHepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation.Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo2024-02-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/rimtsp/article/view/22185110.1590/S1678-9946202466011Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e11Revista do Instituto de Medicina Tropical de São Paulo; v. 66 (2024); e11Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e111678-99460036-4665reponame:Revista do Instituto de Medicina Tropical de São Pauloinstname:Instituto de Medicina Tropical (IMT)instacron:IMTenghttps://www.revistas.usp.br/rimtsp/article/view/221851/202731Copyright (c) 2024 Ana Claudia Marques Barbosa Diaz, Steven Sol Witkin, Cesar de Almeida Neto, Vanderson Rocha, Silvia Figueiredo Costa, Jessica Fernandes Ramos, Maria Cassia Mendes-Correahttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessDiaz, Ana Claudia Marques Barbosa Witkin, Steven Sol Almeida Neto, Cesar de Rocha, VandersonCosta, Silvia Figueiredo Ramos, Jessica Fernandes Mendes-Correa, Maria Cassia 2024-05-06T14:04:52Zoai:revistas.usp.br:article/221851Revistahttp://www.revistas.usp.br/rimtsp/indexPUBhttps://www.revistas.usp.br/rimtsp/oai||revimtsp@usp.br1678-99460036-4665opendoar:2024-05-06T14:04:52Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT)false
dc.title.none.fl_str_mv Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation
title Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation
spellingShingle Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation
Diaz, Ana Claudia Marques Barbosa
Hepatitis C
Hematopoietic stem cell transplantation
Prevalence
Clinical outcome
title_short Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation
title_full Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation
title_fullStr Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation
title_full_unstemmed Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation
title_sort Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation
author Diaz, Ana Claudia Marques Barbosa
author_facet Diaz, Ana Claudia Marques Barbosa
Witkin, Steven Sol
Almeida Neto, Cesar de
Rocha, Vanderson
Costa, Silvia Figueiredo
Ramos, Jessica Fernandes
Mendes-Correa, Maria Cassia
author_role author
author2 Witkin, Steven Sol
Almeida Neto, Cesar de
Rocha, Vanderson
Costa, Silvia Figueiredo
Ramos, Jessica Fernandes
Mendes-Correa, Maria Cassia
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Diaz, Ana Claudia Marques Barbosa
Witkin, Steven Sol
Almeida Neto, Cesar de
Rocha, Vanderson
Costa, Silvia Figueiredo
Ramos, Jessica Fernandes
Mendes-Correa, Maria Cassia
dc.subject.por.fl_str_mv Hepatitis C
Hematopoietic stem cell transplantation
Prevalence
Clinical outcome
topic Hepatitis C
Hematopoietic stem cell transplantation
Prevalence
Clinical outcome
description Hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation.
publishDate 2024
dc.date.none.fl_str_mv 2024-02-07
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/rimtsp/article/view/221851
10.1590/S1678-9946202466011
url https://www.revistas.usp.br/rimtsp/article/view/221851
identifier_str_mv 10.1590/S1678-9946202466011
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/rimtsp/article/view/221851/202731
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo
publisher.none.fl_str_mv Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo
dc.source.none.fl_str_mv Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e11
Revista do Instituto de Medicina Tropical de São Paulo; v. 66 (2024); e11
Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e11
1678-9946
0036-4665
reponame:Revista do Instituto de Medicina Tropical de São Paulo
instname:Instituto de Medicina Tropical (IMT)
instacron:IMT
instname_str Instituto de Medicina Tropical (IMT)
instacron_str IMT
institution IMT
reponame_str Revista do Instituto de Medicina Tropical de São Paulo
collection Revista do Instituto de Medicina Tropical de São Paulo
repository.name.fl_str_mv Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT)
repository.mail.fl_str_mv ||revimtsp@usp.br
_version_ 1798951636651999232